Development and Pilot Testing of a Pharmacist-Led β-Lactam Allergy Risk Assessment Tool for Chinese Patients
Die Pharmazie · 28.04.2026 · 81 (1-4)
DOI: 10.31083/pharmazie51744 ↗Kurz gefasst
Fachartikel in der Zeitschrift Die Pharmazie, online erschienen am 28.04.2026. Verfasst von Xiunan Yue und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, First Hospital of Shanxi Medical University, 030001 Taiyuan, Shanxi, China. Hauptthemen laut MEDLINE: Drug Hypersensitivity, Pharmacists, beta-Lactams, Anti-Bacterial Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background: β-lactam allergy labels (BALs) are commonly found in patient records but are often inaccurate. This can lead to suboptimal antibiotic selection, increased healthcare costs, and antimicrobial resistance. Most existing risk assessment tools were developed in Western settings and are not applicable in Chinese clinical contexts. This study developed and pilot-tested a pharmacist-led BAL risk assessment tool tailored to the Chinese healthcare environment.
Methods
The study was conducted in three phases: (1) A systematic review of 90 studies to identify key β-lactam allergy risk factors; (2) Grounded theory and text co-occurrence analysis to extract high-risk features and construct the assessment framework; and (3) A pilot implementation in a tertiary hospital to evaluate the tool’s feasibility, clinical impact, and patient outcomes using a quasi-experimental design.
Results
The final tool comprised eight dimensions, 35 subdimensions, and over 1328 distinct coded nodes. Of the 289 patients involved in the pilot, 18.7% were classified as high risk. Compared with patients with BALs but without high-risk features, those at lower risk had significantly shorter hospital stays (8.5 ± 4.3 vs. 10.6 ± 5.5 days; p < 0.001), reduced hospitalization costs (17,800 ± 6200 vs. 21,000 ± 7500; p = 0.0011), and lower allergy event rates (0% vs. 6.5%; p = 0.002). β-lactam use increased (75.3% vs. 40.3%; p < 0.001), whereas second-line antibiotic use decreased (24.7% vs. 59.7%; p < 0.001). The tool also demonstrated high feasibility, achieving a 100% completion rate and strong adherence among pharmacists.
Conclusion
This pharmacist-led risk assessment tool has strong potential for accurately identifying high-risk β-lactam allergy patients and optimising antimicrobial stewardship in Chinese hospitals. Further large-scale validation is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, First Hospital of Shanxi Medical University, 030001 Taiyuan, Shanxi, China.
- School of Pharmacy, Shanxi Medical University, 030001 Taiyuan, Shanxi, China.
Zitieren
APA
Yue, X., Shang, N., Chen, W., & Zheng, X. (2026). Development and Pilot Testing of a Pharmacist-Led β-Lactam Allergy Risk Assessment Tool for Chinese Patients. Die Pharmazie, 81(1-4). https://doi.org/10.31083/pharmazie51744
Vancouver
Yue X, Shang N, Chen W, Zheng X. Development and Pilot Testing of a Pharmacist-Led β-Lactam Allergy Risk Assessment Tool for Chinese Patients. Die Pharmazie. 2026;81(1-4). doi:10.31083/pharmazie51744
BibTeX
@article{Yue2026,
author = {Yue, Xiunan and Shang, Nan and Chen, Wanying and Zheng, Xiaojun},
title = {Development and Pilot Testing of a Pharmacist-Led β-Lactam Allergy Risk Assessment Tool for Chinese Patients},
journal = {Die Pharmazie},
year = {2026},
volume = {81},
number = {1-4},
doi = {10.31083/pharmazie51744}
}
EUVIMED